Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
NCT06881290
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG:
Vunakizumab (IL-17A inhibitor)
Sponsor
Chinese SLE Treatment And Research Group